Children's Cancer Therapy Development Institute collaborates globally with Atomwise using newly published AI technology
The breadth of this collaboration across so many types of proteins and the observation that these computational-derived compounds bound and affected function of these proteins is remarkable.”
HILLSBORO, OREGON, UNITED STATES, April 2, 2024 /EINPresswire.com/ -- The Children’s Cancer Therapy Development Institute (cc-TDI), proudly announces a global Artificial Intelligence (AI) collaboration with Atomwise, resulting in a new publication in the journal Scientific Reports.— Scientific Director, Charles Keller MD
The paper, "AI is a viable alternative to high throughput screening: a 318‑target study" comes from the AI computation drug design company, Atomwise (https://www.atomwise.com/) in San Francisco, CA, USA. cc-TDI was among 282 Institutions across the world to work with Atomwise to use the AtomNet artificial intelligence model, which is a graph convolution network architecture, to predict compounds that dock to a given disease-related protein. cc-TDI previously published results of their target in the British Journal of Cancer (https://www.nature.com/articles/s41416-023-02222-0) related to the adolescent and young adult cancer, Clear Cell Sarcoma.
cc-TDI's Scientific Director Charles Keller MD remarked, "the breadth of this collaboration across so many types of proteins (enzymes, nuclear receptors, transcription factors, DNA/RNA binding proteins, ion channels, transporters and GPCRs) and the observation that these computational-derived compounds bound and affected function of these proteins is remarkable". cc-TDI has done similar work with the IBM-created World Community Grid (https://www.worldcommunitygrid.org/research/scc1/researchers.s) and related pilot studies with Microsoft Azure HPC (https://techcommunity.microsoft.com/t5/azure-global/large-scale-docking-for-drug-design-on-azure/ba-p/4044613), lending confidence that the first stage of drug development can be rapid, inexpensive, and tractable for rare childhood cancers.
About cc-TDI: The Children’s Cancer Therapy Development Institute (cc-TDI, www.cc-tdi.org), is a 501c3 non-profit biotech organization whose mission is to translate scientific discovery into clinical trials by understanding and proving new disease-specific treatment options for children with cancer. cc-TDI’s research team of biologists and engineers work closely to identify targets on cancer cells and provide evidence-based testing for the selection of new drugs to be used in childhood cancer phase I and phase II clinical trials.
Erika Ellis
Children's Cancer Therapy Development Institute
+1 503-985-6016
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Instagram
TikTok
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
